Stay updated on Imsidolimab in Generalized Pustular Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page.

Latest updates to the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content removal, including the objectives and criteria for a study on imsidolimab for Generalized Pustular Psoriasis, as well as the name of the study director. A new version number has been added.SummaryDifference8%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check45 days agoChange DetectedDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check88 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
Stay in the know with updates to Imsidolimab in Generalized Pustular Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Imsidolimab in Generalized Pustular Psoriasis Clinical Trial page.